EXTH-44. PERSONALIZED IMMUNOTHERAPY VACCINES FOR GLIOBLASTOMA AND THEIR TREATMENT EFFICACY

Abstract BACKGROUND Glioblastoma multiforme (GBM) remains a disease with debilitating survival outcomes. Cancer immunogenomics represents complementary approach to the application of genomics in developing novel immunotherapies for brain malignancies. Using cancer that we developed, called Open Reading Frame Antigen Network (O.R.A.N.), identified immunogenic neoantigens and tumor-associated antigens (TAAs) including cancer-testis developmental antigens, are aberrantly overexpressed murine models GBM. The aim this study is evaluate immunologic effects safety immunotherapy vaccines targeting TAAs preclinical METHODS RNAseq WES were performed glioblastoma tumors- KR158-Luc GL261, results fed O.R.A.N pipeline antigen prediction. A tumor antigen-specific RNA library was created each using gene enrichment strategy validated by RNAseq. Tumor-bearing animals treated adoptively transferred ex vivo expanded lymphocytes dendritic cell loaded RNA. Tumor volume, thus progress, determined luciferase imaging technique outcomes noted. We also evaluated efficacy combination checkpoint blockade therapy treating tumor-bearing combined an anti-PD-1 antibody. RESULTS significantly effective slowing progression GBM tumors both adoptive cellular as well therapy. Additionally, T cells several our predicted increase tumor-infiltrating memory animals. CONCLUSION developed cell-based vaccination being tumor-specific